The general meaning of a word is the representation of the type from it, in linguistic contexts and certain grammatical forms and this meaning is opposed to the individualized meaning, the separation of a unique item of the type, distinguishable from others. The general meaning seems like a grammatical meaning that is not formally sufficiently marked, but the indefinite articles and the suffixes, in addition to other grammatical meanings, can also express a general meaning in certain contexts. A definite meaning of the noun is generally considered the meaning of the noun in the definite form and indefinite meaning the one of the indefinite noun. But how does the general meaning relate to them? Nouns with general meaning, whether in the indefinite form or in the definite form are meaningfully definite. Both the speaker and the listener know the class that the general noun marks. Despite the formal indefiniteness / definiteness, nouns with a general meaning are semantically definite.

Anglisticum

The seeds of Cleome viscosa are used in traditional systems of medicine for the treatment of many diseases in Asia. This study evaluated fixed oil from the seeds of Cleome viscosa for analgesic and antiemetic activity by using the acetic acid induced writhing test in mice (intraperitoneally) and chick emetic model (oral treatment) respectively. The results showed significant analgesic and antiemetic activities of Cleome viscosa fixed oil.

Dr. salman ahmed

This review shares historical glimpses of the art and science of urinary crystal growth in the gel. This successful journey of long and detailed research consists of theoretical and experimental knowledge. The survey consists of historical aspects of crystal growth, the development of urinary crystal growth in the gel as an in vitro urolithiasis model and the application of this model to evaluate prophylactic management against kidney stones.

Dr. salman ahmed

Diabetes mellitus (DM) is a complex and chronic illness requiring continuous medical care. Type 2 diabetes (T2D) is commonly associated with obesity, hypertension, and a tendency to develop thrombosis, and an increase risk of cardiovascular diseases (CVD). Diabesity is a term used to indicate the coexistence of obesity and DM. Diabesity increases as obesity is an emerging epidemic in modern societies, the co-incidence with DM is also rising, so a joint plan of anti-obesity and anti-hyperglycemia for the management approaches. Therefore, this study aimed to identify the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on body weight and glycemic response in obese Libyan patients with T2D at the National Diabetes Centre in Tripoli, between July 2013 and May 2022. This prospective study included obese adults with T2D who were newly prescribed GLP-1RA therapy for six months with dulaglutide once weekly or liraglutide once daily. The study included 170 diabetic patients who were started on GLP1-RA as add on therapy to their treatment, with a regular follow-up with dietitian and their physicians to adjust their glucose-lowering medications, then comparing the effect of these agents on body weight and the level of glycated hemoglobin before and after 24 weeks of treatment. Most of the patients (n = 99, 58.23%) were in the age period from 54 to 74 years old and 101 of whom were female subjects (59.4%), with a mean duration of DM equal to 8.8 ± 7.3 years. The patients were divided randomly into two groups, the first group included 110 patients who received liraglutide pens showed a significant reduction in HbA1c from 9.6% (± 1.54) to 7.4% (± 1.03) by p < 0.001 and a significant weight loss from 88.3 kg (± 10.68) to 80.8 kg (± 11.83) by p < 0.001. The reported adverse events were in 23 cases of minor hypoglycemia due to gastrointestinal upset. The other group included 60 patients for dulaglutide pens and showed significant decrease in HbA1c = 9.6% (± 1.54) to 7.1% (± 1.2) by p < 0.05 and a significant reduction of bodyweight from 88.3 kg (± 10.68) to 83.8 kg (± 16.3) by p < 0.05. The reported adverse events were mild transient gastrointestinal distress for the initial week of a start and then subside with regular intake. Whereas, 115 patients (67.6%) with HbA1c above 10.0% before starting therapy, no patient with HbA1c above 10.0% after six months of both GLP-RA agents therapy. Thus, the uses of GLP-RA as add-on therapy for obese patients with T2D significantly improved glycaemic control with less hypoglycaemia, accordingly, reduce insulin requirement for blood glucose control and loss in body weight. It can thus be concluded that GLP-1RA therapy is an effective treatment option when used in obese patients with DM.

Mediterranean journal of pharmacy and pharmaceutical sciences